Clinical trials
Relapse clinical trials
Below are recruiting relapse clinical trials, each written for real people, not researchers. We’re tracking 892 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07369895RecruitingPhase 1
A new cell therapy for relapsed or refractory multiple myeloma
This trial tests a new cell therapy (O&D-001) for multiple myeloma that has returned or not responded to previous treatments. It targets specific markers on myeloma cells (BCMA or GPRC5D) and aims to shrink the cancer.
Guangzhou, GuangdongAges 18–75 - NCT07347418RecruitingPhase 1
CD64 CAR T cell therapy for relapsed or refractory AML
This trial tests a type of immunotherapy called CAR T cells that target a protein called CD64 on leukemia cells. It is for adults with AML that has come back or not responded to treatment, including venetoclax.
Aurora, ColoradoAges 18 years+ - NCT07334301RecruitingPhase 1/Phase 2
Combination treatments for relapsed high-risk neuroblastoma
This trial is testing different combinations of medicines for children with high-risk neuroblastoma that has come back. It has two paths: one for children whose disease has relapsed only once, and another for those whose disease has come back more than once. The goal is to find which treatments work best.
SydneyAges 1 year+ - NCT07321093RecruitingPhase 3
A study of BCD-281 for relapsing-remitting MS
This trial tests a new medicine called BCD-281 for people with relapsing-remitting multiple sclerosis (RRMS). It aims to see if the drug can reduce relapses and improve disease control.
Nizhny NovgorodAges 18–55 - NCT07320235RecruitingPhase 1
Combination treatment for relapsed AML
This trial tests a new combination of drugs for people whose acute myeloid leukemia (AML) has come back or not responded after at least one prior treatment, and who have no other standard options. The goal is to see if adding imetelstat to other therapies can help.
New York, New YorkAges 18 years+ - NCT06581081Recruiting
CAR-T therapy with or without stem cell transplant for B-cell leukemia
This trial tests a CD19-targeted CAR-T cell therapy (S1904) for people with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. After CAR-T, some patients may go on to a stem cell transplant. The goal is to see if the CAR-T can lead to remission and who needs a transplant.
Beijing, Beijing MunicipalityAges 12–65 - NCT06873100RecruitingPhase 1/Phase 2
Upadacitinib for relapsing polychondritis
This trial tests whether upadacitinib, an oral medication, is safe and effective for people with relapsing polychondritis that hasn't improved enough with standard treatments. It aims to reduce inflammation and control symptoms.
Beijing, Beijing MunicipalityAges 18–70 - NCT07312188RecruitingPhase 2
F182112 for relapsed or refractory multiple myeloma
This trial tests a new drug, F182112, for people whose multiple myeloma came back or didn't respond to prior treatments that included lenalidomide and a proteasome inhibitor. It may help if your disease has active signs like high protein levels.
TianjinAges 18 years+ - NCT07292480Recruiting
Monthly NfL monitoring for relapsing-remitting MS
This trial tests whether monthly blood tests for a nerve protein (NfL) can detect hidden disease activity in people with relapsing-remitting multiple sclerosis (RRMS) who are on certain first-line treatments. It aims to find out if this monitoring helps catch early signs of active disease before symptoms appear.
NiceAges 18–55 - NCT07284433RecruitingPhase 1/Phase 2
Donor cell therapy for B-cell blood cancers
This trial tests a new treatment made from donor cells that target two proteins (CD19 and CD20) found on certain blood cancer cells. It may be an option for people whose B-cell lymphoma or chronic lymphocytic leukemia has come back or hasn't responded to at least two prior treatments.
Chicago, IllinoisAges 18 years+ - NCT07271953Recruiting
Help for new moms to stay smoke-free after pregnancy
This trial tests if motivational interviews and a digital game can help women who quit smoking early in pregnancy avoid restarting after giving birth. You will receive support through counseling and a game to stay smoke-free.
Ankara, AnkaraAges 18 years+ - NCT07271121RecruitingPhase 2
CAR T cells for CD19+ aggressive lymphoma
This trial tests a personalized treatment where your own immune cells are modified to find and kill lymphoma cells that have a protein called CD19. It may be an option if your lymphoma has returned or not responded to standard treatments.
AmmanAges 18–75 - NCT06484829RecruitingPhase 1/Phase 2
New drug combo for relapsed or refractory multiple myeloma
This trial tests a new drug, purinostat mesylate, combined with pomalidomide (a chemotherapy pill) and a low-dose steroid (dexamethasone) for people with multiple myeloma that has returned or stopped responding to prior treatments. The goal is to see if this combination can help control the cancer with manageable side effects.
Chengdu, SichuanAges 18–75 - NCT07234110Recruiting
CD5 CAR-T therapy for returning blood cancers
This trial tests a new treatment using your own immune cells, modified to find and attack cancer cells that have a CD5 marker. It may be an option for people with certain lymphomas or leukemia that have not responded to standard treatments or have come back.
Tianjin, Tianjin MunicipalityAges 1–70 - NCT07225361RecruitingPhase 4
Ublituximab for early relapsing multiple sclerosis
This study tests ublituximab (Briumvi), a treatment given as an infusion, for people recently diagnosed with relapsing MS. The goal is to see if starting this treatment early helps control MS better.
Chicago, IllinoisAges 18–70 - NCT07220252RecruitingPhase 2/Phase 3
Ublituximab for children with relapsing multiple sclerosis
This trial tests a new drug called ublituximab to see if it can reduce flare-ups in children and teens who have relapsing multiple sclerosis. It aims to understand if the treatment is safe and effective for younger patients.
GdanskAges 10–17 - NCT07198230Recruiting
DEB-TACE therapy for large lymphoma tumors that have returned or not responded
This trial tests a second-line treatment called DEB-TACE (tiny beads filled with chemo placed directly into the tumor's blood supply) for people with large, hard-to-treat lymphoma tumors that have come back or not responded to other therapies. If you have at least one big tumor with good blood supply and have tolerated doxorubicin chemo before, this might be an option.
Fuzhou, FujianAges 18–75 - NCT07189325RecruitingPhase 3
Comparing two ways to manage relapsing-remitting MS
This trial tests if it's safe to stop or reduce anti-CD20 treatment after several years of stable disease, compared to continuing it. It's for people with relapsing-remitting MS who are at least 40 years old and have had no MS activity for the past 3 years on anti-CD20 therapy.
MontpellierAges 40 years+ - NCT07161258RecruitingPhase 2
Fenebrutinib for children with relapsing MS
This study tests a new oral medication called fenebrutinib for children and teenagers with relapsing multiple sclerosis. It aims to find the right dose and see how safe and effective it is compared to standard treatments.
Rosario, Santa Fe ProvinceAges 10–17 - NCT06686108RecruitingPhase 2
Medication combo to prevent lymphoma relapse after transplant
This trial tests a combination of two drugs (a demethylating agent and venetoclax) to help prevent high-risk T-cell lymphoma or leukemia from coming back after a stem cell transplant. It is for patients who have certain risk factors for relapse.
ShanghaiAges 14–55 - NCT07138209RecruitingPhase 3
Comparing QLS32015 to standard treatments for multiple myeloma
This trial tests a new drug, QLS32015, against two common treatments for multiple myeloma that has come back or not responded to therapy. It may be an option for people who have already tried several treatments.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07137637RecruitingPhase 1
HPB-092 for relapsed or refractory AML
This trial tests a new drug, HPB-092, in adults with acute myeloid leukemia that has come back or not responded to treatment. The goal is to see if it can help when other treatments have not worked.
TianjinAges 18 years+ - NCT07144254RecruitingPhase 1
Tegavivint and gemcitabine for relapsed osteosarcoma
This trial tests a new drug called tegavivint combined with the chemotherapy drug gemcitabine for people whose osteosarcoma has come back or stopped responding to treatment. The goal is to see if this combination can help shrink or control the cancer.
Atlanta, GeorgiaAges 1–30 - NCT07116616RecruitingPhase 1/Phase 2
mRNA vaccine for relapsed or refractory multiple myeloma
This trial tests an experimental mRNA therapy called mRNA-2808 for people with multiple myeloma that has returned or stopped responding to prior treatments. It aims to see if it can help control the disease.
Birmingham, AlabamaAges 18 years+
Hear when a new Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapse?
- Yes. Clin2 currently lists 892 recruiting relapse studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapse trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapse trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.